Rachel Yehuda

20120039812, Feb 16, 2012

Sep 14, 2009

13/063696

Florian Holsboer - Munich, DE
Marcus Ising - Munich, DE
Rachel Yehuda - Bronx NY, US
Joseph D. Buxbaum - New York NY, US

A61K 49/00
C12Q 1/68
C40B 30/04

424 92, 506 9, 435 612, 435 613

The present invention relates to a method of identifying a predisposition for developing posttraumatic stress disorder (PTSD) in a subject comprising assessing in a sample obtained from said subject the expression level of one or more genes selected from the FK506 binding protein 5 (FKBP5) gene, the signal transducer and activator of transcription (STAT5B) gene and the nuclear factor I/A (NFIA) gene, wherein a decrease in the expression level of said one or more genes as compared to the expression level of the corresponding gene(s) of a control is indicative of a predisposition for developing PTSD. Further, the invention relates to a method of identifying a compound capable of preventing or treating PTSD or capable of serving as a lead compound for developing a compound capable of preventing or treating PTSD and also to a method of selecting a therapy to prevent or treat PTSD.